Sandoz eyes US biosimilar launch as Regeneron settles

Deal resolves just one case in Regeneron’s roll-call of actions against competitors looking to launch versions of a $6bn-a-year blockbuster eye-disease treatment.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Regeneron hits Amgen over its blockbuster eye disease treatment

19 June 2025 The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.

Americas

Regeneron edges closer to Eylea market exclusivity amid biosimilar threats

6 March 2025 New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.

Americas

Courtroom report: Regeneron’s $6bn biosimilar battle against Mylan

13 February 2025 The company’s Eylea treatment patent faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.

More features

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

Smart ringleader: Could Ōura’s market dominance be under threat?

Sandoz eyes US biosimilar launch as Regeneron settles

More on this story

Editor's picks

Editor's picks

More features